Varicella Attenuated Live Vaccination Market Report – Research, Industry Analysis Reports and Market Demands

Global Varicella Attenuated Live Vaccination Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Varicella Attenuated Live Vaccination Consumption Value by Type: 2020 Versus 2024 Versus 2031
- 1.3.2 Monovalent Vaccine
- 1.3.3 Combination Vaccine
1.4 Market Analysis by Application
- 1.4.1 Overview: Global Varicella Attenuated Live Vaccination Consumption Value by Application: 2020 Versus 2024 Versus 2031
- 1.4.2 Children
- 1.4.3 Adults
1.5 Global Varicella Attenuated Live Vaccination Market Size & Forecast
- 1.5.1 Global Varicella Attenuated Live Vaccination Consumption Value (2020 & 2024 & 2031)
- 1.5.2 Global Varicella Attenuated Live Vaccination Sales Quantity (2020-2031)
- 1.5.3 Global Varicella Attenuated Live Vaccination Average Price (2020-2031)

2 Manufacturers Profiles

3 Competitive Environment: Varicella Attenuated Live Vaccination by Manufacturer

3.1 Global Varicella Attenuated Live Vaccination Sales Quantity by Manufacturer (2020-2025)
3.2 Global Varicella Attenuated Live Vaccination Revenue by Manufacturer (2020-2025)
3.3 Global Varicella Attenuated Live Vaccination Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
- 3.4.1 Producer Shipments of Varicella Attenuated Live Vaccination by Manufacturer Revenue ($MM) and Market Share (%): 2024
- 3.4.2 Top 3 Varicella Attenuated Live Vaccination Manufacturer Market Share in 2024
- 3.4.3 Top 6 Varicella Attenuated Live Vaccination Manufacturer Market Share in 2024
3.5 Varicella Attenuated Live Vaccination Market: Overall Company Footprint Analysis
- 3.5.1 Varicella Attenuated Live Vaccination Market: Region Footprint
- 3.5.2 Varicella Attenuated Live Vaccination Market: Company Product Type Footprint
- 3.5.3 Varicella Attenuated Live Vaccination Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Varicella Attenuated Live Vaccination Market Size by Region
- 4.1.1 Global Varicella Attenuated Live Vaccination Sales Quantity by Region (2020-2031)
- 4.1.2 Global Varicella Attenuated Live Vaccination Consumption Value by Region (2020-2031)
- 4.1.3 Global Varicella Attenuated Live Vaccination Average Price by Region (2020-2031)
4.2 North America Varicella Attenuated Live Vaccination Consumption Value (2020-2031)
4.3 Europe Varicella Attenuated Live Vaccination Consumption Value (2020-2031)
4.4 Asia-Pacific Varicella Attenuated Live Vaccination Consumption Value (2020-2031)
4.5 South America Varicella Attenuated Live Vaccination Consumption Value (2020-2031)
4.6 Middle East & Africa Varicella Attenuated Live Vaccination Consumption Value (2020-2031)

5 Market Segment by Type

5.1 Global Varicella Attenuated Live Vaccination Sales Quantity by Type (2020-2031)
5.2 Global Varicella Attenuated Live Vaccination Consumption Value by Type (2020-2031)
5.3 Global Varicella Attenuated Live Vaccination Average Price by Type (2020-2031)

6 Market Segment by Application

6.1 Global Varicella Attenuated Live Vaccination Sales Quantity by Application (2020-2031)
6.2 Global Varicella Attenuated Live Vaccination Consumption Value by Application (2020-2031)
6.3 Global Varicella Attenuated Live Vaccination Average Price by Application (2020-2031)

7 North America

7.1 North America Varicella Attenuated Live Vaccination Sales Quantity by Type (2020-2031)
7.2 North America Varicella Attenuated Live Vaccination Sales Quantity by Application (2020-2031)
7.3 North America Varicella Attenuated Live Vaccination Market Size by Country
- 7.3.1 North America Varicella Attenuated Live Vaccination Sales Quantity by Country (2020-2031)
- 7.3.2 North America Varicella Attenuated Live Vaccination Consumption Value by Country (2020-2031)
- 7.3.3 United States Market Size and Forecast (2020-2031)
- 7.3.4 Canada Market Size and Forecast (2020-2031)
- 7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

8.1 Europe Varicella Attenuated Live Vaccination Sales Quantity by Type (2020-2031)
8.2 Europe Varicella Attenuated Live Vaccination Sales Quantity by Application (2020-2031)
8.3 Europe Varicella Attenuated Live Vaccination Market Size by Country
- 8.3.1 Europe Varicella Attenuated Live Vaccination Sales Quantity by Country (2020-2031)
- 8.3.2 Europe Varicella Attenuated Live Vaccination Consumption Value by Country (2020-2031)
- 8.3.3 Germany Market Size and Forecast (2020-2031)
- 8.3.4 France Market Size and Forecast (2020-2031)
- 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
- 8.3.6 Russia Market Size and Forecast (2020-2031)
- 8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

9.1 Asia-Pacific Varicella Attenuated Live Vaccination Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Varicella Attenuated Live Vaccination Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Varicella Attenuated Live Vaccination Market Size by Region
- 9.3.1 Asia-Pacific Varicella Attenuated Live Vaccination Sales Quantity by Region (2020-2031)
- 9.3.2 Asia-Pacific Varicella Attenuated Live Vaccination Consumption Value by Region (2020-2031)
- 9.3.3 China Market Size and Forecast (2020-2031)
- 9.3.4 Japan Market Size and Forecast (2020-2031)
- 9.3.5 South Korea Market Size and Forecast (2020-2031)
- 9.3.6 India Market Size and Forecast (2020-2031)
- 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
- 9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

10.1 South America Varicella Attenuated Live Vaccination Sales Quantity by Type (2020-2031)
10.2 South America Varicella Attenuated Live Vaccination Sales Quantity by Application (2020-2031)
10.3 South America Varicella Attenuated Live Vaccination Market Size by Country
- 10.3.1 South America Varicella Attenuated Live Vaccination Sales Quantity by Country (2020-2031)
- 10.3.2 South America Varicella Attenuated Live Vaccination Consumption Value by Country (2020-2031)
- 10.3.3 Brazil Market Size and Forecast (2020-2031)
- 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

11.1 Middle East & Africa Varicella Attenuated Live Vaccination Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Varicella Attenuated Live Vaccination Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Varicella Attenuated Live Vaccination Market Size by Country
- 11.3.1 Middle East & Africa Varicella Attenuated Live Vaccination Sales Quantity by Country (2020-2031)
- 11.3.2 Middle East & Africa Varicella Attenuated Live Vaccination Consumption Value by Country (2020-2031)
- 11.3.3 Turkey Market Size and Forecast (2020-2031)
- 11.3.4 Egypt Market Size and Forecast (2020-2031)
- 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
- 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

12.1 Varicella Attenuated Live Vaccination Market Drivers
12.2 Varicella Attenuated Live Vaccination Market Restraints
12.3 Varicella Attenuated Live Vaccination Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Varicella Attenuated Live Vaccination and Key Manufacturers
13.2 Manufacturing Costs Percentage of Varicella Attenuated Live Vaccination
13.3 Varicella Attenuated Live Vaccination Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Varicella Attenuated Live Vaccination Typical Distributors
14.3 Varicella Attenuated Live Vaccination Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Varicella Attenuated Live Vaccination market size was valued at US$ 2786 million in 2024 and is forecast to a readjusted size of USD 3380 million by 2031 with a CAGR of 2.8% during review period.
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Varicella Attenuated Live Vaccination market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Varicella Attenuated Live Vaccination market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Varicella Attenuated Live Vaccination market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Varicella Attenuated Live Vaccination market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Varicella Attenuated Live Vaccination market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Varicella Attenuated Live Vaccination
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Varicella Attenuated Live Vaccination market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, BCHT, Shanghai Institute, GSK, Keygen, Green Cross, Biken, Shanghai Rongsheng Biotech, Changsheng, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Varicella Attenuated Live Vaccination market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Monovalent Vaccine
Combination Vaccine
Market segment by Application
Children
Adults
Major players covered
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changsheng
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Varicella Attenuated Live Vaccination product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Varicella Attenuated Live Vaccination, with price, sales quantity, revenue, and global market share of Varicella Attenuated Live Vaccination from 2020 to 2025.
Chapter 3, the Varicella Attenuated Live Vaccination competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Varicella Attenuated Live Vaccination breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Varicella Attenuated Live Vaccination market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Varicella Attenuated Live Vaccination.
Chapter 14 and 15, to describe Varicella Attenuated Live Vaccination sales channel, distributors, customers, research findings and conclusion.

Buy now